A health worker takes a nasal swab sample of an Indian police man in plain clothes to test for COVID-19 inside a park in Srinagar. (Photo | AP)

Nation

First COVID nasal vaccine by Bharat Biotech gets regulator's nod for holding phase 2, 3 clinical trials

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, the Department of Biotechnology said.

PTI

Updated:14th Aug, 2021 at 12:13 AM

NEW DELHI: The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.

ALSO READ | India's drug regulator approves study on mixing of Covaxin and Covishield doses

"Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials," the DBT said.

This is the first of its kind COVID-19 jab to undergo human clinical trials in India.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.

Bharat Biotech has in-licensed technology from Washington University in St Louis, US.

First COVID nasal vaccine by Bharat Biotech gets regulator's nod for holding phase 2, 3 clinical trials

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, the Department of Biotechnology said.

Also Read

LIVE | US, Israel trade strikes with Iran as IRGC warns of 'complete destruction' of regional infrastructure

Hegseth says US 'can't stop everything' that Iran fires even as he asserts air dominance

Tamil Nadu polls: Deadlock ends as DMK allots Congress 28 seats, one Rajya Sabha berth

At least 87 killed as Iranian warship sinks in Indian Ocean after US submarine strike

Rupee plumbs new low, breaches 92 mark as Iran war escalates